Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
13F holders, Q3 2024
Institutional positions in Belite Bio, Inc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +4 vs. Q2 2024
- Shares held
- 78.7K
- −107.9K (−57.8%) vs. Q2 2024
- Total value
- $3.69M
- −$4.83M (−56.7%) vs. Q2 2024
- New holders
- 6
- 5 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLTE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 80 | $1.44B |
| Q1 2026 | 75 | $1.42B |
| Q4 2025 | 69 | $1.15B |
| Q3 2025 | 34 | $169.3M |
| Q2 2025 | 18 | $4.51M |
| Q1 2025 | 18 | $9.91M |
| Q4 2024 | 22 | $17.8M |
| Q3 2024 | 15 | $3.69M |
| Q2 2024 | 11 | $8.52M |
| Q1 2024 | 11 | $2.23M |
| Q4 2023 | 17 | $7.10M |
| Q3 2023 | 7 | $3.17M |
| Q2 2023 | 6 | $14.9M |
| Q1 2023 | 8 | $25.4M |
| Q4 2022 | 7 | $25.9M |
| Q3 2022 | 8 | $3.87M |
| Q2 2022 | 6 | $2.15M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Belite Bio, Inc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Street Corp | 20,086 | $941.6K | 0.00% | +4,415+28.2% | Added |
| Bank of America Corp | 13,451 | $630.6K | 0.00% | +13,349+13,087.3% | Added |
| Marshall Wace, LLP | 8,486 | $397.8K | 0.00% | +8,486 | New |
| Geode Capital Management, LLC | 6,700 | $314.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 6,460 | $302.8K | 0.00% | +6,460 | New |
| JPMorgan Chase & Co | 6,356 | $298.0K | 0.00% | +6,268+7,122.7% | Added |
| XTX Topco Ltd | 5,394 | $252.9K | 0.02% | +5,394 | New |
| Point72 Asset Management, L.P. | 4,800 | $225.0K | 0.00% | −2,511−34.3% | Reduced |
| Cubist Systematic Strategies, LLC | 2,019 | $94.7K | 0.00% | +2,019 | New |
| Virtus ETF Advisers LLC | 1,843 | $86.4K | 0.04% | +36+2.0% | Added |
| Rhumbline Advisers | 1,435 | $67.3K | 0.00% | +1,435 | New |
| GAMMA Investing LLC | 871 | $40.8K | 0.00% | +443+103.5% | Added |
| Morgan Stanley | 662 | $31.0K | 0.00% | −382−36.6% | Reduced |
| UBS Group AG | 128 | $6.00K | 0.00% | +128 | New |
| Advisor Group Holdings, Inc. | 8 | $375 | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −148,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −5,409−100.0% | Sold out |